Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Biogen Inc. < Previous 1 2 Next > UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024 September 24, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen Board Appoints Two New Independent Directors September 12, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA September 04, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB IONS New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC) July 30, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease July 30, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB DHR Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union July 26, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen Completes Acquisition of Human Immunology Biosciences July 02, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China June 27, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease June 09, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel June 03, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS May 30, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences May 22, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis May 16, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB IONS Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status May 14, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen Reports Progress on Corporate Responsibility Priorities May 02, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy March 06, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB IONS Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting March 04, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP February 23, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia February 12, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen to Realign Resources for Alzheimer's Disease Franchise January 31, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission December 19, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease December 15, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. December 14, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB SAGE Biogen Appoints Monish Patolawala to its Board of Directors November 06, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On October 25, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease October 25, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting October 19, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA® September 29, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen Completes Acquisition of Reata Pharmaceuticals September 26, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB RETA LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan September 25, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.